Opinions about scientific advances blur party-political lines
By Matthew Nisbet and Ezra Markowitz,
The Conversation
| 02. 19. 2014
Reading about the rapid pace of advances in biomedicine, you may have wondered why more politically liberal countries like Germany and Canada have stronger restrictions on embryonic stem cell research than the politically conservative US.
History and happenstance play a role, but these differences also reflect public concerns that do not conform to traditional left or right political ideologies.
As debates over stem cell research continue and as conflicts over other biomedical advances emerge, a recurring set of questions is likely to be seen. Do scientific breakthroughs promote or undermine social progress? Is research being pursued too cautiously or too quickly? Do scientists respect or cross moral boundaries?
In a study, just published in PLOS ONE, we analysed a series of surveys collected between 2002 and 2010 to better understand what the US public thinks about stem cell research and how they formed these opinions. We were able to distinguish between the different factors influencing their beliefs. At play were factors such as traditional loyalties to political parties and more fundamental beliefs about science and society.
Our results indicate...
Related Articles
By Charles Schmidt, Undark | 09.25.2026
In 2010, scientists at the University of Tokyo and other institutions reported a startling achievement: They had successfully grown a pancreas made almost entirely of rat cells within the bodies of mice. The research was directed by Hiromitsu Nakauchi, a...
By Editors, Nature | 08.18.2026
Shinya Yamanaka doesn’t see himself as a celebrity. But people do recognize the stem-cell researcher when he’s out for a run, often while training for a marathon, on the streets of Kyoto, Japan.
Many of them call out words of...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...
By Carl Zimmer and Marco Hernandez , The New York Times | 07.01.2026
Scientists have long dreamed of discovering the alchemy by which chemicals can be turned into life. On Wednesday, a team at the University of Minnesota announced that it had taken a major step toward that vision.
Blending together dozens of...